12th Jul 2016 08:16
LONDON (Alliance News) - Cell engineering technology supplier MaxCyte Inc on Tuesday said trading in the first half of 2016 was in line with its expectations.
The company, which floated on AIM in March, said revenue for the first half was not less than USD5.4 million, up 30% on the USD4.2 million reported a year prior.
MaxCyte said it has continued to expand its customer base and said the development of its CARMA platform and its pipeline of cell therapies has progressed to plan.
"With consistently increasing visibility of revenues, we are trading in line with our expectations for the full year. Both the CARMA and partnered cell therapy programs are progressing well. We look forward to the future with great confidence," said MaxCyte Chief Executive Doug Doerfler.
Shares in MaxCyte were up 4.6% to 85.25 pence early Tuesday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
MaxCyte